Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial | Zendy

Suzanne L. Topalian | Zendy; Shailender Bhatia | Zendy; Asim Amin | Zendy; Ragini R. Kudchadkar | Zendy; William H. Sharfman | Zendy; Célèste Lebbé | Zendy; JeanPierre Delord | Zendy; Lara Dunn | Zendy; Michi M. Shinohara | Zendy; Rima M. Kulikauskas | Zendy; Christine H. Chung | Zendy; Uwe M. Martens | Zendy; Robert L. Ferris | Zendy; Julie E. Stein | Zendy; Elizabeth L. Engle | Zendy; Lot A. Devriese | Zendy; Christopher D. Lao | Zendy; Junchen Gu | Zendy; Bin Li | Zendy; Tian Chen | Zendy; Adam Barrows | Zendy; Andrea Horváth | Zendy; Janis M. Taube | Zendy; Paul Nghiem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

Author(s) -

Suzanne L. Topalian,

Shailender Bhatia,

Asim Amin,

Ragini R. Kudchadkar,

William H. Sharfman,

Célèste Lebbé,

JeanPierre Delord,

Lara Dunn,

Michi M. Shinohara,

Rima M. Kulikauskas,

Christine H. Chung,

Uwe M. Martens,

Robert L. Ferris,

Julie E. Stein,

Elizabeth L. Engle,

Lot A. Devriese,

Christopher D. Lao,

Junchen Gu,

Bin Li,

Tian Chen,

Adam Barrows,

Andrea Horváth,

Janis M. Taube,

Paul Nghiem

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.00201

Subject(s) - medicine , merkel cell carcinoma , nivolumab , merkel cell polyomavirus , adverse effect , cancer , oncology , surgery , carcinoma , gastroenterology , immunotherapy

Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC frequently responds to PD-1 blockade. We report what we believe to be the first trial of anti-PD-1 in the neoadjuvant setting for resectable MCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research